vRad Announces Clinical Trials Partnership With ICON Medical Imaging
Virtual Radiologic
(vRad), a technology-enabled national radiology practice, has announced a premier radiology partnership with
ICON Medical Imaging
(ICON), the medical imaging division of ICON plc.
ICON Medical Imaging provides medical imaging-based product development services to the pharmaceutical biotechnology and medical device industries. The partnership with vRad will enable ICON Medical Imaging to access the breadth and depth of vRad's subspecialty expertise and to obtain high-quality interpretations provided by vRad's fellowship-trained radiologists.
The first clinical trial involving vRad launched in September, with more expected to rapidly follow. This partnership will provide a great opportunity for vRad radiologists to make an impact on advancing healthcare. The use of imaging in clinical trials has been recognized by the pharmaceutical industry to assist in measuring early results, thereby helping to shorten the timeline for bringing effective drugs to market, and saving costs and lives in the process.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
